202865-70-1 Usage
Uses
Used in Pharmaceutical Research and Development:
2-Bromo-5-fluorocinnamic acid is utilized as a building block in the synthesis of various biologically active molecules, contributing to its importance as a synthetic intermediate in the pharmaceutical industry. Its unique structure allows for the development of new drugs with potential therapeutic applications.
Used in Organic Synthesis:
As a reagent in organic reactions, 2-Bromo-5-fluorocinnamic acid facilitates the creation of a range of chemical compounds. Its presence in these reactions can lead to the formation of new molecules with specific properties, broadening the scope of chemical research and development.
Used in the Preparation of Functionalized Cinnamic Acid Derivatives:
2-Bromo-5-fluorocinnamic acid serves as a starting material for the preparation of functionalized cinnamic acid derivatives. These derivatives can have various applications in different fields, such as in the creation of new pharmaceuticals, agrochemicals, or other specialty chemicals.
Check Digit Verification of cas no
The CAS Registry Mumber 202865-70-1 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,0,2,8,6 and 5 respectively; the second part has 2 digits, 7 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 202865-70:
(8*2)+(7*0)+(6*2)+(5*8)+(4*6)+(3*5)+(2*7)+(1*0)=121
121 % 10 = 1
So 202865-70-1 is a valid CAS Registry Number.
InChI:InChI=1/C9H6BrFO2/c10-8-3-2-7(11)5-6(8)1-4-9(12)13/h1-5H,(H,12,13)/b4-1+
202865-70-1Relevant academic research and scientific papers
AMINOINDAN DERIVATIVE OR SALT THEREOF
-
Page/Page column 13, (2009/04/23)
Provided is a compound that is an NMDA receptor antagonist having a broader safety margin, and is useful as an agent for treating or preventing Alzheimer's disease, cerebrovascular dementia, Parkinson's disease, ischemic apoplexy, or pain. A novel compound or a salt thereof, which is characterized in that it has an amino group and R1(lower alkyl, cycloalkyl, -lower alkylene-aryl, aryl which may be substituted, and the like) on carbon atoms of indane, cyclopenta[b]thiophene, cyclopenta[b]furan, cyclopenta[b]pyridine, or cyclopenta[c]pyridine ring, or 2,3-dihydrdo-1-benzofuran, 2,3-dihydrdo-1-benzothiophene, indoline ring, or the like, and has R2 and R3 (the same or different, each lower alkyl or aryl) on carbon atoms beside them, and an NMDA receptor antagonist comprising the same as an active component.
